Search

Displaying results 6311 - 6320 of 10000 in total
  1. Drug

    Recombinant CD40-ligand

    go.drugbank.com/drugs/DB15015
    Investigational

    Recombinant CD40-ligand is under investigation in clinical trial NCT00053391 (Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma).

  2. Drug

    Nolatrexed

    go.drugbank.com/drugs/DB12912
    Experimental

    Nolatrexed is under investigation in clinical trial NCT00012324 (Nolatrexed Dihydrochloride Compared With Doxorubicin in Treating Patients With Recurrent or Unresectable Liver Cancer).

  3. Drug

    Lurtotecan

    go.drugbank.com/drugs/DB12222
    Investigational

    Lurtotecan is under investigation in clinical trial NCT00022594 (Liposomal Lurtotecan in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer).

  4. Drug

    ARX517

    go.drugbank.com/drugs/DB23076
    Investigational

    ARX517 is under investigation in clinical trial NCT04662580 (ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer).

  5. Drug

    Ditekiren

    go.drugbank.com/drugs/DB19992
    Experimental

    Ditekiren is a small molecule drug. The usage of the INN stem '-kiren' in the name indicates that Ditekiren is a renin inhibitor. Ditekiren has a monoisotopic molecular weight of 929.57 Da.

    Categories: Agents Acting on the Renin-Angiotensin System
  6. Drug

    SIS-101-ADO

    go.drugbank.com/drugs/DB18085
    Experimental

    SIS-101-ADO is a siRNA therapeutic under investigation for the treatment of Autosomal Dominant Osteopetrosis Type 2 (ADO2).[L48091]

  7. Drug

    N-sulfoglucosamine sulfohydrolase recombinant

    go.drugbank.com/drugs/DB12722
    Investigational

    N-sulfoglucosamine sulfohydrolase recombinant is under investigation for the treatment of Mucopolysaccharidosis III and Sanfilippo Syndrome Type A (MPS IIIA).

  8. Drug

    Ganetespib

    go.drugbank.com/drugs/DB12047
    Investigational

    Ganetespib is under investigation for the treatment of BREAST CANCER, Small Cell Lung Cancer, Acute Myeloid Leukaemia, and Myelodysplastic Syndrome.

  9. Drug

    Ciluprevir

    go.drugbank.com/drugs/DB05868
    Investigational

    The compound, named BILN 2061, is an orally active inhibitor of the HCV NS3 protease and the first member of this new drug class to be tested in humans.

  10. Drug

    Sulfaperin

    go.drugbank.com/drugs/DB13320
    Experimental

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use